Syneron Reports Fourth Quarter and Full Year 2013 Results 4Q13 revenue of $64.3 million excluding contribution from Syneron Beauty revenue after its de-consolidation on December 8, 2013 following closing of the Unilever JV; 4Q13 non-GAAP EPS $0.11

When excluding Syneron Beauty: Non-GAAP operating margin increased from 2.2% to 5.2% in Q413 and from 2.1% to 5.1% annually and Q413 EPS increased by 5 cents to $0.16 and almost doubled EPS for FY 2013

President Amit Meridor Appointed CEO; Dr. Shimon Eckhouse Returning as Active Chairman; Steve Fanning and Dominick Arena Joining the Board of Directors

YOKNEAM, Israel, Feb. 20, 2014 /PRNewswire/ -- Syneron Medical Ltd. (NASDAQ: ELOS), the leading global aesthetic device company, today announced financial results for the three month and full year periods ended December 31, 2013.

(Logo: http://photos.prnewswire.com/prnh/20120528/535447 )

Fourth Quarter 2013 and Recent Highlights Include:

  • Completed global joint venture, Iluminage Beauty, with Unilever for home beauty devices, triggering the de-consolidation of Syneron Beauty as of December 8, 2013
  • Total reported revenue of $64.3 million (included Syneron Beauty revenue until December 8, 2013), down 12% year-over-year compared to 4Q12, which included a large, multi-site customer order that did not recur in 2013, but increased sequentially from 3Q13 by 3%
  • PAD[1] segment reported revenue of $58.8 million, down 10% year-over-year compared to 4Q12, which included the large, multi-site customer order and  $0.9 million impact to 4Q13 due to the continued devaluation of the Japanese yen
  • EBU[2] segment reported revenue of $5.5 million, down 23% year-over-year representing partial quarter of Syneron Beauty's revenues, following its de-consolidation as of December 8, 2013
  • Non-GAAP gross margin of 53.7%, up from 53.0% in 4Q12 and 53.1% in 3Q13
  • PAD segment non-GAAP operating margin of 7.0%, down from 12.3% in 4Q12; PAD segment GAAP operating margin of 10.3%, up from 2.4% in 4Q12
  • Non-GAAP EPS of $0.11 which includes a one-time non-GAAP net tax benefit of $0.09 mainly as a result of the tax assessments and settlement reached with the Israeli tax authorities for years 2007-2011
  • Syneron's 49% share of Iluminage Beauty valued at $24.7 million, generating gain, net of deal related costs, of $6.0 million or $0.16 GAAP EPS
  • GAAP EPS of $0.27 which includes a one-time GAAP net tax benefit of $0.21 mainly as a result of the tax assessments and settlement and the completion of a U.S. entity consolidation implemented during the fourth quarter of 2013, in addition to the above
  • Acquired Cooltouch, Inc., thereby expanding product offering and the consumable model

Fourth Quarter 2013 Pro-Forma (Excluding Syneron Beauty) Financial Highlights Include:

  • Total pro-forma revenue of $59.9 million, compared to total revenue of $64.3 million
  • Non-GAAP pro-forma gross margin of 55.0%, compared to non-GAAP gross margin of 53.7%
  • Non-GAAP pro-forma operating margin of 5.2%, compared to non-GAAP operating margin of 2.2%
  • Non-GAAP pro-forma EPS of $0.16, compared to non-GAAP EPS of $0.11

Dr. Shimon Eckhouse, active Chairman of Syneron, commented, "In 2013 we made several strategic changes to our leadership team and operational plan focused on positioning the Company to achieve revenue growth and expanded profitability. We made good progress with these changes during the fourth quarter, including the continued expansion of our North American sales force, the advancement of our new product initiatives, including our UltraShape and VelaShape III products, and the streamlining of our operating infrastructure. We also entered into a global joint venture with Unilever for home beauty devices that allows us to benefit from the growth potential of the joint venture while eliminating the financial demands of building a consumer business."

Amit Meridor, newly appointed Chief Executive Officer of Syneron, said, "In North America, we achieved another quarter of double-digit growth from the higher margin Syneron product line, driven by the expansion of our sales team and added focus on the non-core segment of the market. We expect to continue building out the North American team with additional sales representatives, marketing personnel and clinical support during the first half of 2014. We also remain on track for the potential FDA clearance of UltraShape in the first half of 2014, which along with VelaShape III, would give us a significant offering in the fast growing non-invasive body shaping and fat treatment market."

Mr. Meridor added, "With the acquisition of Cooltouch, Inc. expected to close in March, we will further expand our product portfolio. The Cooltouch portfolio of laser-based systems and disposables address two significant indications of minimally invasive laser lipolysis and the reimbursable varicose veins treatment, both of which are new market opportunities for Syneron. We believe a key benefit of the acquisition is that it is aligned with our strategy to enhance the consumable business model. It also gives us an entry into surgical aesthetics with an approved and reimbursable product and an established customer base."

Dr. Eckhouse concluded, "In 2014, we will focus on positioning the Company for improved financial results through continued investments in our North American sales and marketing team and our new product pipeline. We expect some top-line growth in 2014, with higher growth in North America due to our expanded sales team and focus on the non-core market, and growth in Europe, driven by market stabilization and more direct sales. Additional key revenue drivers for the year are expected to include VelaShape III and the initial rollout of UltraShape, which we are expecting in the second half of 2014. We also expect improved margins due to the de-consolidation of Syneron Beauty from our consolidated results, our strategic initiatives to increase sales of higher margin products and consumables, and a full year benefit from our cost reduction initiatives. Longer-term, we believe all of these factors will position Syneron to achieve well above market, double-digit revenue growth and improved operating leverage."

Revenue: Fourth quarter 2013 reported revenue was $64.3 million, down 12% compared to $72.8 million in the fourth quarter 2012, which included a large multi-site PAD order.

PAD segment revenue was $58.8 million, down 10% compared to $65.6 million in the fourth quarter 2012, which included a large multi-site order. Excluding this large order, the PAD segment was driven by higher revenue in North America, including strong growth in sales of Syneron products, and the EMEA, partially offset by lower revenue in the Asia-Pacific and Latin American regions. Fourth quarter 2013 PAD segment revenue was also negatively impacted by $0.9 million due to the devaluation of the Japanese Yen against the U.S. dollar compared to the fourth quarter 2012.

EBU segment revenue was $5.5 million, down 23% compared to $7.2 million in the fourth quarter 2012. On December 8, 2013, Syneron entered into a global joint venture (Iluminage Beauty) with Unilever for home beauty devices that included its Syneron Beauty subsidiary. As a result, the Company recorded a partial quarter of Syneron Beauty revenue results within the EBU segment, compared to a full quarter of revenue in the fourth quarter 2012. From December 8 to December 31, 2013, Syneron Beauty generated $2.8 million in sales as part of Iluminage Beauty. A table detailing Syneron's pro-forma 2013 quarterly and annual results on a Non-GAAP basis excluding Syneron Beauty is included at the end of this press release.

Non-GAAP Financial Highlights for the Fourth Quarter Ended December 31, 2013:

Gross Margin for the fourth quarter 2013 was 53.7%, up from 53.0% in the fourth quarter 2012,primarily due to favorable product mix in the PAD segment, partially offset by lower gross margin in the EBU segment. Gross margin for the fourth quarter 2013 increased sequentially from 53.1% in the third quarter 2013.

Operating Income for the fourth quarter 2013 was $1.4 million, compared to $5.7 million in the fourth quarter 2012 which was mainly driven by the above mentioned large multi-site order, representing an operating margin of 2.2% of revenue in the fourth quarter 2013, compared to 7.8% in the fourth quarter 2012.

Net Income and Earnings Per Share in the fourth quarter 2013 were $4.0 million, or $0.11 per share, compared to net income of $4.1 million, or $0.11 per share, in the fourth quarter 2012. Fourth quarter net income and earnings per share included a net tax benefit of $3.3 million, or $0.09 per share, mainly related to the Company's tax settlement with the Israeli tax authorities, which resulted in the conclusion of the Company's Israeli tax audits for the years 2007 to 2011, partially offset by other tax charges.

Net income and earnings per share for the fourth quarter 2013 are adjusted to exclude the following items, which are detailed in the Company's financial tables presented at the end of this press release:

  • Gain, net of deal related costs, related to the Iluminage Beauty joint venture with Unilever of $6.0 million
  • Amortization of acquired intangible assets of $1.6 million
  • Other non-recurring costs of $2.1 million, mainly related to impairment of affiliated company and intangible assets
  • Stock-based compensation of $1.2 million
  • Re-measurement of contingent consideration of $0.3 million
  • Income tax positive adjustment of $4.9 million, including $1.4 million related to the tax settlement with the Israeli tax authorities, $3.0 million other one-time tax items mainly related to U.S. entity consolidation implemented during the fourth quarter 2013 and $0.5 million related to amortization of acquired intangible assets and other non-recurring costs    

GAAP Financial Highlights for the Fourth Quarter Ended December 31, 2013:

Gross Margin for the fourth quarter 2013 was 50.7%, up from 49.5% in the fourth quarter 2012, primarily due to favorable product mix in the PAD segment, partially offset by lower gross margin in the EBU segment. Gross margin for the fourth quarter 2013 slightly decreased sequentially from 50.9% in the third quarter 2013.

Operating Income for the fourth quarter 2013 was $2.2 million, compared to an operating loss of $1.7 million in the fourth quarter 2012. Fourth quarter 2013 operating income included a gain, net of deal related costs, of $6.0 million related to the Company's global joint venture with Unilever for home beauty devices that commenced in December 2013.

Net Income and Earnings Per Share in the fourth quarter 2013 was $9.7 million, or $0.27 per share, compared to net income of $5.2 million, or $0.15 per share, in the fourth quarter 2012. Fourth quarter net income and earnings per share included a gain, net of deal related costs, of $6.0 million as mentioned above, related to the Company's global joint venture with Unilever for home beauty devices that commenced in December 2013 and a tax benefit of $4.8 million mainly related to the Company's tax settlement of past years with the Israeli tax authorities, net of the approximately $4 million paid on trapped profits that was reported in November 2013 and $3.0 million other one-time tax benefit mainly related to U.S. entity consolidation implemented during the fourth quarter of 2013. This one-time tax benefit is in addition to the amount included in the Company's non-GAAP figures.

Cash Position: As of December 31, 2013, the Company's cash and cash equivalents was $108.5 million.

Hugo Goldman, Chief Financial Officer of Syneron, said, "Our non-GAAP pro-forma fourth quarter results, which excluded Syneron Beauty, demonstrate the improved profitability profile of our business without this home-use subsidiary. Non-GAAP pro-forma revenue for the fourth quarter and full year 2013 was $59.9 million and $232.1 million, respectively. For the same periods, non-GAAP pro-forma gross margin was 55.0% and 54.7%, respectively, compared to consolidated non-GAAP gross margin of 53.7% and 53.0%, respectively. Fourth quarter and full year 2013 non-GAAP pro-forma operating margin was 5.2% and 5.1%, respectively, compared to consolidated non-GAAP operating margin of 2.2% and 2.1%, respectively. On the bottom line, non-GAAP pro-forma EPS was $0.16 in the fourth quarter 2013 and $0.37 for the full year 2013, compared to consolidated non-GAAP EPS of $0.11 and $0.19, respectively. Our fourth quarter 2013 consolidated non-GAAP EPS of $0.11 included a $0.09 tax benefit as explained above."

Mr. Goldman added, "On a GAAP-basis, fourth quarter net income and earnings per share benefitted from the tax assessment and settlement with the Israeli tax authorities, net of other tax liabilities, which amounted to $4.8 million or a net benefit of approximately $0.13 per share, which resulted in a one-time payment of approximately $4 million that freed up $63.7 million in "trapped profits". On a non-GAAP basis, the net benefit was approximately $0.09 per share. This tax assessment and tax settlement resulted in the conclusion of our Israeli tax audits for the years 2007 to 2011. In addition our GAAP results include $3.0 million of other one-time tax benefit mainly related to U.S. entity consolidation we implemented during the fourth quarter of 2013. We ended the year with $108.5 million in cash and cash equivalents to support continued investments in the growth of our business."

Management and Board of Directors Update

Syneron announced the appointment of President Amit Meridor to the position of Chief Executive Officer, effective immediately. He replaces Dr. Shimon Eckhouse, who will return to the position of Chairman of the Board of Directors. Since joining Syneron in July 2013 as President, Mr. Meridor has played a key role in the implementation of the Company's strategic initiatives, including the expansion of the North American sales force, advancing new product initiatives, and streamlining the Company's operating infrastructure. David Schlachet, who served as Chairman of the Board during Dr. Eckhouse's tenure as Chief Executive Officer, will remain on the Board.

The Company also announced the addition of two directors to its Board of Directors: Stephen Fanning and Dominick Arena. Mr. Fanning previously served as President and Chief Executive Officer of Solta Medical from 2005 to 2013, and as Chairman of the Company from 2006 to 2013. Solta Medical is an aesthetic device company that was acquired by Valeant Pharmaceuticals International, Inc. in January 2014. From August 2001 to January 2005, Mr. Fanning served as the President and Chief Executive Officer of Ocular Sciences, a manufacturer and seller of disposable contact lenses. Previously, Mr. Fanning served in various senior executive positions at Johnson & Johnson for over 25 years.

Mr. Fanning commented, "It is an exciting time to join the Syneron Board of Directors. The Company is well positioned within the aesthetic industry and has a strategic plan to achieve long-term revenue growth and margin expansion. I look forward to bringing my industry perspective to the Board to further refine the Company's strategy and build shareholder value."

Mr. Arena currently serves as an operating partner with Water Street Healthcare Partners, a strategic private equity firm focused exclusively on the healthcare industry. He previously served on the Syneron Board of Directors, joining in March 2012 and serving through May 2013, at which point he left the Board due to personal reasons. The Company is pleased to welcome Mr. Arena back to the Board of Directors.


Unaudited Non-GAAP segments results for the three months ended December 31, 2013 and 2012 (in thousands):











For the three-months ended





December 31,

% of 

December 31,

% of 

% of 




2013

Revenues 

2012

Revenues 

Change


















Revenues
















PAD

$            58,784

91.4%

$            65,605

90.2%

(10.4%)



EBU

5,498

8.6%

7,155

9.8%

(23.2%)










Total revenues

$            64,282

100.0%

$            72,760

100.0%

(11.7%)


















Operating income (loss)
















PAD

$              4,134

7.0%

$              8,055

12.3%

(48.7%)



EBU

(2,689)

(48.9%)

(2,353)

(32.9%)

(14.3%)










Total operating income

$              1,445

2.2%

$              5,702

7.8%

(74.7%)


 

Unaudited Non-GAAP segment results for the twelve months ended December 31, 2013 and 2012 (in thousands):











For the twelve-months ended





December 31,

% of 

December 31,

% of 

% of 




2013

Revenues 

2012

Revenues 

Change


















Revenues
















PAD

$           226,445

88.1%

$           236,516

89.7%

(4.3%)



EBU

30,470

11.9%

27,106

10.3%

12.4%










Total revenues

$           256,915

100.0%

$           263,622

100.0%

(2.5%)


















Operating income (loss)
















PAD

$            14,969

6.6%

$            24,499

10.4%

(38.9%)



EBU

(9,478)

(31.1%)

(13,296)

(49.1%)

(28.7%)










Total operating income 

$              5,491

2.1%

$            11,203

4.2%

(51.0%)


 

Unaudited GAAP segments results for the three months ended December 31, 2013 and 2012 (in thousands):










For the three-months ended




December 31,

% of 

December 31,

% of 

% of 



2013

Revenues 

2012

Revenues 

Change















Revenues














PAD

$            58,784

91.4%

$            65,605

90.2%

(10.4%)


EBU

5,498

8.6%

7,155

9.8%

(23.2%)








Total revenues

$            64,282

100.0%

$            72,760

100.0%

(11.7%)















Operating income (loss)














PAD

$              6,073

10.3%

$              1,601

2.4%

279.3%


EBU

(3,830)

(69.7%)

(3,300)

(46.1%)

(16.0%)








Total operating income (loss)

$              2,243

3.5%

$             (1,699)

(2.3%)

232.0%

 

Unaudited GAAP segment results for the twelve months ended December 31, 2013 and 2012 (in thousands):










For the twelve-months ended




December 31,

% of 

December 31,

% of 

% of 



2013

Revenues 

2012

Revenues 

Change















Revenues














PAD

$           226,445

88.1%

$           236,516

89.7%

(4.3%)


EBU

30,470

11.9%

27,106

10.3%

12.4%








Total revenues

$           256,915

100.0%

$           263,622

100.0%

(2.5%)















Operating income (loss)














PAD

$              6,996

3.1%

$              8,930

3.8%

(21.7%)


EBU

(13,115)

(43.0%)

(16,698)

(61.6%)

(21.5%)








Total operating loss

$             (6,119)

(2.4%)

$             (7,768)

(2.9%)

(21.2%)

 

Syneron Medical Ltd.

Unaudited Non-GAAP Financial Measures and Reconciliation

















For the three-months ended




December 31, 2013


December 31, 2012




EBU


PAD


Total


EBU


PAD


Total






























GAAP operating income (loss) 

$             (3,830)


$                6,073


$              2,243


$             (3,300)


$                1,601


$             (1,699)

















Stock-based compensation

186


997


1,183


98


1,275


1,373



Amortization of intangible assets

332


1,304


1,636


449


1,644


2,093



Remeasurement of Contingent consideration

-


339


339


-


(1,293)


(1,293)



Gain from sale of subsidiary, net of deal related costs

-


(6,020)


(6,020)


-


-


-



Other non-recurring items

623


1,441


2,064


400


4,828


5,228
















Non-GAAP operating income (loss)

$             (2,689)


$                4,134


$              1,445


$             (2,353)


$                8,055


$              5,702


























































Syneron Medical Ltd.

Unaudited Non-GAAP Financial Measures and Reconciliation

















For the twelve-months ended




December 31, 2013


December 31, 2012




EBU


PAD


Total


EBU


PAD


Total






























GAAP operating income (loss) 

$           (13,115)


$                6,996


$             (6,119)


$           (16,698)


$                8,930


$             (7,768)

















Stock-based compensation

479


4,009


4,488


318


4,420


4,738



Amortization of intangible assets

1,500


5,505


7,005


1,465


6,594


8,059



Remeasurement of Contingent consideration

-


1,209


1,209


-


(1,836)


(1,836)



Gain from sale of subsidiary, net of deal related costs

-


(6,020)


(6,020)


-


-


-



Other non-recurring items

1,658


3,270


4,928


1,619


6,391


8,010
















Non-GAAP operating income (loss)

$             (9,478)


$              14,969


$              5,491


$           (13,296)


$              24,499


$            11,203
















 

Use of Non-GAAP Measures

This press release provides financial measures for gross margin, operating margin, operating income (loss), net income (loss), earnings (loss) per share, which exclude expenses related to stock-based compensation, amortization and impairment of intangible assets, one-time severance, other non-recurring items such as costs associated with the voluntary field action regarding the LiteTouch Dental Laser Product in Europe, and income tax adjustment, and are therefore not calculated in accordance with generally accepted accounting principles (GAAP). Management believes that these non-GAAP financial measures provide meaningful supplemental information regarding our performance because it reflects our ongoing operational results, operating margin, operating income (loss), net income (loss) and earnings (loss) per share. The presentation of this non-GAAP financial information is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP. Management uses non-GAAP measures when evaluating the business internally and, therefore, felt it important to make these non-GAAP adjustments available to investors. A reconciliation of each GAAP to non-GAAP financial measure discussed in this press release is contained in the accompanying financial tables.

Conference call

Syneron management will host its fourth quarter and full year 2013 earnings conference call today at 8:30 a.m. ET. Syneron will be broadcasting live via the Investor Relations section of its website, www.investors.syneron.com. To access the call, enter the Syneron Investor Relations website, then click on the webcast link "Q4 2013 Results Webcast."

Participants are encouraged to log on at least 15 minutes prior to the conference call in order to download the applicable audio software. The call can be heard live or with an on-line replay which will follow. Those interested in participating in the call and the question and answer session should dial 877-844-6886 in the U.S., and 970-315-0315 from overseas. The conference pass code is: 46590042.

About Syneron Medical Ltd.

Syneron Medical Ltd. (NASDAQ: ELOS) is the leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company's technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, rejuvenation of the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under two distinct brands, Syneron and Candela. Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. are located in Israel. Syneron also has R&D and manufacturing operations in the U.S. The Company markets, services and supports its products in 90 countries. It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide.

SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS

Any statements contained in this document regarding future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Further, any statements that are not statements of historical fact (including statements containing "believes," "anticipates," "plans," "expects," "may," "will," "would," "intends," "estimates" and similar expressions) should also be considered to be forward-looking statements. Forward-looking statements in this press release include our expectation that the Unilever JV would allow us to benefit from the growth potential of the JV while eliminating the financial demands of building a consumer business; our expectation for some top-line growth in 2014, with higher growth in North America due to our expanded sales team and focus on the non-core market, and in Europe, driven by market stabilization and more direct sales; additional key revenue drivers for 2014 expected to include VelaShape III and the initial rollout of UltraShape, which we are expecting in the second half of 2014 after potential FDA clearance in the first half of 2014; our expectation of  improved margins due to the deconsolidation of Syneron Beauty from our consolidated results, our strategic initiatives to increase sales of higher margin products and consumables, and a full year benefit from our cost reduction initiatives; and our belief that Syneron is positioned to achieve well above market, double-digit revenue growth and improved operating leverage in the long term. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including the risks set forth in Syneron Medical Ltd.'s most recent Annual Report on Form 20-F, and the other factors described in the filings that Syneron Medical Ltd. makes with the SEC from time to time.  If one or more of these factors materialize, or if any underlying assumptions prove incorrect, Syneron Medical Ltd.'s actual results, performance or achievements may vary materially from any future results, performance or achievements expressed or implied by these forward-looking statements.

In addition, the statements in this document reflect the expectations and beliefs of Syneron Medical Ltd. as of the date of this document.  Syneron Medical Ltd. anticipates that subsequent events and developments will cause its expectations and beliefs to change.  However, while Syneron Medical Ltd. may elect to update these forward-looking statements publicly in the future, it specifically disclaims any obligation to do so.  The forward-looking statements of Syneron Medical Ltd. do not reflect the potential impact of any future dispositions or strategic transactions that may be undertaken.  These forward-looking statements should not be relied upon as representing Syneron Medical Ltd.'s views as of any date after the date of this document.

Syneron, the Syneron logo, eMatrix and elos are trademarks of Syneron Medical Ltd. and may be registered in certain jurisdictions. The elos (Electro-Optical Synergy) technology is a proprietary technology of Syneron Medical Ltd. All other names are the property of their respective owners.

[1] PAD: Professional Aesthetic Device segment, which includes the results of the Syneron and Candela device businesses.

[2] EBU: Emerging Business Units. Products in the EBU include me home-use hair removal system, elure Advanced Skin Brightening products, Tanda LED systems, Light Instruments' dental laser devices along with pipeline products that include Fluorinex teeth whitening and fluorination. On December 8, 2013, Syneron entered a global joint venture with Unilever for home beauty devices that included its Syneron Beauty subsidiary and related products (me home-use hair removal system, Pearl teeth whitening and Tanda LED systems). As of the above date, Syneron de-consolidated Syneron Beauty and its subsidiaries from the consolidated company reports.

 

 

Syneron Medical Ltd.

Unaudited Condensed Consolidated Statements of Operations

(in thousands, except per share data)












For the three-months ended


For the twelve-months ended



December 31,


December 31,


December 31,


December 31,



2013


2012


2013


2012



















Revenues

$            64,282


$            72,760


$           256,915


$           263,622

Cost of revenues 

31,716


36,715


126,838


127,182










Gross profit

32,566


36,045


130,077


136,440










Operating expenses:









Sales and marketing 

21,006


18,685


82,445


77,795


General and administrative

7,770


8,701


28,378


34,188


Research and development

7,040


8,306


29,996


29,936


Other expenses (income), net

(5,493)


2,052


(4,623)


2,289










Total operating expenses

30,323


37,744


136,196


144,208










Operating Income (loss)

2,243


(1,699)


(6,119)


(7,768)











Financial Income (expenses), net 

324


(49)


26


925










Income (Loss) before tax benefit

2,567


(1,748)


(6,093)


(6,843)










Tax benefit

(7,147)


(6,700)


(7,640)


(4,502)










Income (Loss) before non-controlling interest

9,714


4,952


1,547


(2,341)










Net loss attributable to non-controlling interest

-


222


100


998










Income (Loss) attributable to Syneron shareholders

$              9,714


$              5,174


$              1,647


$             (1,343)




























Income (Loss) per share:

















Basic 









Income (Loss) before non-controlling interest

$                0.27


$                0.14


$                0.04


$               (0.07)


Net loss attributable to non-controlling interest

-


0.01


-


0.03


Net income (loss) attributable to Syneron shareholders

$                0.27


$                0.15


$                0.04


$               (0.04)










Diluted









Income (Loss) before non-controlling interest

$                0.27


$                0.14


$                0.04


$               (0.07)


Net loss attributable to non-controlling interest

-


0.01


-


0.03


Net income (loss) attributable to Syneron shareholders

$                0.27


$                0.15


$                0.04


$               (0.04)



















Weighted average shares outstanding:









Basic 

36,208


35,587


35,922


35,475











Diluted

36,523


35,808


36,204


35,475

 

Syneron Medical Ltd.

Condensed Consolidated Balance Sheets

(in thousands)








December 31,


December 31,



2013


2012 (*)



(Unaudited)



Assets









Current assets:





Cash and cash equivalents

$              37,583


$              66,359


Short-term bank deposits

16,453


20,520


Available-for-sale marketable securities

28,933


41,136


Trade receivable, net

54,229


50,023


Other accounts receivables and prepaid expenses

14,262


12,563


Inventories

34,707


36,862






Total current assets

186,167


227,463






Long-term assets:





Severance pay fund

565


600


Long-term deposits and others 

1,509


1,879


Long-term available-for-sale marketable securities 

25,571


7,966


Investment in affiliated company

24,720


1,000


Property and equipment, net

6,603


6,148


Intangible assets, net 

21,439


30,433


Goodwill

20,976


25,219


Deferred taxes

17,927


18,390






Total long-term assets

119,310


91,635






Total assets

$            305,477


$            319,098











Liabilities and Stockholders' Equity









Current liabilities:





Accounts payable

$              17,679


$              19,926


Deferred revenues

13,001


11,986


Other accounts payable and accrued expenses

27,831


49,889






Total current liabilities

58,511


81,801






Long-term liabilities:





Contingent consideration liability

7,896


6,750


Deferred revenues

3,461


3,924


Warranty accruals

779


708


Accrued severance pay

611


691


Deferred taxes

2,430


3,095






Total long-term liabilities

15,177


15,168






Stockholders' equity:

231,789


222,129






Total liabilities and stockholders' equity

$            305,477


$            319,098






 (*)

Derived from audited financial statements




 

Syneron Medical Ltd.

 Unaudited Condensed Consolidated Statements of Cash Flows

(in thousands)









For the twelve-months ended























December 31,



December 31,









2013



2012

Cash flows from operating activities:








Net Income (loss) before non-controlling interest



$              1,547



$           (2,341)



Adjustments to reconcile net loss to net cash
 used by operating activities:









Non-cash items reported in discontinued operations









Share-based compensation 



4,489



4,734



Depreciation and amortization



10,469



10,981



Impairments of intangible assets



323



3,820



Gain from sale of subsidiary



(7,273)



-



Realized loss, changes in accrued interest and amortization of premium (discount) on marketable securities



1,074



(758)



Impairment of investment in affiliated company



1,000



200



Revaluation of contingent liability



1,146



(1,910)



Changes in operating assets and liabilities










Trade receivable, net



(9,367)



(6,697)




Inventories



(10,860)



(7,072)




Other accounts receivables



(352)



775




Deferred taxes



(2,279)



(12,064)




Accounts payable



2,236



(2,134)




Deferred revenue



1,030



406




Accrued warranty accruals



(229)



676




Other accrued liabilities



(14,907)



304















Net cash used in operating activities



(21,953)



(11,080)















Cash flows from investing activities:









Purchases of property and equipment



(3,661)



(1,993)



Proceeds from the sale or maturity of marketable securities



52,185



71,032



Purchase of marketable securities



(58,745)



(33,281)



Proceeds from short-term bank deposits, net



4,081



3,268



Investments in affiliated company



-



(1,000)



Deconsolidation of subsidiary



(320)



(15,064)



Other investing activities



(366)



(202)















Net cash provided by (used in) investing activities



(6,826)



22,760













Cash flows from financing activities:









Short term bank credit, net



-



(1,082)



Acquisition of shares held by non-controlling  shareholders of  a subsidiary



(5,156)



(7,200)



Proceeds from exercise of stock options



7,232



1,950















Net cash provided by (used in) financing activities



2,076



(6,332)













Effect of exchange rates on cash and cash equivalents



(2,073)



(1,308)













Net increase (decrease) in cash and cash equivalents



(28,776)



4,040















Cash and cash equivalents at beginning of period



66,359



62,319















Cash and cash equivalents at end of period



$            37,583



$           66,359

 

Syneron Medical Ltd.

Unaudited Non-GAAP Financial Measures and Reconciliation

(in thousands, except per share data)












For the three-months ended


For the twelve-months ended



December 31,


December 31,


December 31,


December 31,



2013


2012


2013


2012



















GAAP operating income (loss)

$              2,243


$             (1,699)


$             (6,119)


$             (7,768)











Stock-based compensation

1,183


1,373


4,488


4,738


Amortization of intangible assets

1,636


2,093


7,005


8,059


Gain from sale of subsidiary, net of deal related costs

(6,020)


-


(6,020)


-


Remeasurement of contingent consideration 

339


(1,293)


1,209


(1,836)


Other non-recurring items

2,064


5,228


4,928


8,010










Non-GAAP operating income

$              1,445


$              5,702


$              5,491


$            11,203



























GAAP net income (loss) attributable to Syneron shareholders

$              9,714


$              5,174


$              1,647


$             (1,343)











Stock-based compensation

1,183


1,373


4,488


4,738


Amortization of intangible assets

1,636


2,093


7,005


8,059


Gain from sale of subsidiary, net of deal related costs

(6,020)


-


(6,020)


-


Remeasurement of contingent consideration 

339


(1,293)


1,209


(1,836)


Other non-recurring items

2,064


5,228


4,928


8,010


Income tax adjustments

(4,933)


(8,475)


(6,431)


(10,111)










Non-GAAP net income (loss) attributable to Syneron shareholders

$              3,983


$              4,100


$              6,826


$              7,517



















Income (Loss) per share:

















Basic








GAAP net income (loss) per share attributable to Syneron shareholders 

$                0.27


$                0.15


$                0.05


$               (0.04)











Stock-based compensation

0.03


0.04


0.12


0.13


Amortization of intangible assets

0.05


0.06


0.20


0.23


Gain from sale of subsidiary, net of deal related costs

(0.17)


-


(0.17)


-


Remeasurement of contingent consideration 

0.01


(0.04)


0.03


(0.05)


Other non-recurring items

0.06


0.15


0.14


0.23


Income tax adjustments

(0.14)


(0.24)


(0.18)


(0.29)










Non-GAAP net income per share attributable to Syneron shareholders 

$                0.11


$                0.12


$                0.19


$                0.21



















Diluted








GAAP net income (loss) attributable to Syneron shareholders 

$                0.27


$                0.14


$                0.05


$               (0.04)











Stock-based compensation

0.03


0.04


0.12


0.13


Amortization of intangible assets

0.04


0.06


0.19


0.22


Gain from sale of subsidiary, net of deal related costs

(0.16)


-


(0.17)


-


Remeasurement of contingent consideration 

0.01


(0.04)


0.03


(0.05)


Other non-recurring items

0.06


0.15


0.14


0.22


Income tax adjustments

(0.13)


(0.24)


(0.18)


(0.28)










Non-GAAP net income per share attributable to Syneron shareholders 

$                0.11


$                0.11


$                0.19


$                0.21










Weighted average shares outstanding:


















Basic

36,208


35,587


35,922


35,475











Diluted

36,652


35,807


36,254


35,881

 

Syneron Medical Ltd.

Unaudited Non-GAAP Condensed Consolidated Statements of Operations

Pro Forma Basis, Excluding Syneron Beauty

(in thousands, except per share data)






















First Quarter
2013


Second Quarter
2013


Third Quarter
2013


Fourth Quarter
2013


Full Year
2013











Revenues

55,701


60,892


55,657


59,879


232,129

Cost of revenues 

24,571


28,366


25,331


26,921


105,189











Gross profit

31,130


32,526


30,326


32,958


126,940











Operating Income 

2,382


3,388


2,859


3,140


11,769











Income attributable to Syneron shareholders

2,247


3,012


2,460


5,803


13,522











Income per share:




















Basic










Net Income attributable to Syneron shareholders

0.06


0.08


0.07


0.16


0.38











Diluted










Net Income attributable to Syneron shareholders

0.06


0.08


0.07


0.16


0.37











Weighted average shares outstanding:










Basic 

35,621


35,786


36,064


36,208


35,922











Diluted

35,991


36,011


36,196


36,652


36,254

 

 

Syneron Medical Ltd.

Unaudited Non-GAAP Financial Measures and Reconciliation

Pro Forma Basis, Excluding Syneron Beauty

(in thousands, except per share data)











For the three-months ended




As Reported


Syneron Beauty


Pro Forma Basis, Excluding Syneron Beauty




3/31/2013


3/31/2013


3/31/2013


















GAAP operating loss

$             (2,600)


$               (1,745)


$                    (855)











Stock-based compensation

1,021


79


942



Amortization of intangible assets

1,634


152


1,482



Remeasurement of contingent consideration 

318


-


318



Other non-recurring items

495


-


495










Non-GAAP operating income (loss)

$                 868


$               (1,514)


$                  2,382

























GAAP net loss attributable to Syneron shareholders

$             (2,443)


$               (1,802)


$                    (641)








-



Stock-based compensation

1,021


79


942



Amortization of intangible assets

1,634


152


1,482



Remeasurement of contingent consideration 

318


-


318



Other non-recurring items

495


-


495



Income tax adjustments

(393)


(44)


(349)











  Non-GAAP net income (loss) attributable to Syneron shareholders

$                 632


$               (1,615)


$                  2,247


















Income (Loss) per share:















Basic







GAAP net loss per share attributable to Syneron shareholders 
  





$                   (0.02)











Stock-based compensation





0.03



Amortization of intangible assets





0.04



Remeasurement of contingent consideration 





0.01



Other non-recurring items





0.01



Income tax adjustments





(0.01)











Non-GAAP net income per share attributable to Syneron shareholders 





$                    0.06


















Diluted







GAAP net loss attributable to Syneron shareholders  





$                   (0.02)











Legal settlement costs 








Stock-based compensation





0.03



Amortization of intangible assets





0.04



Remeasurement of contingent consideration 





0.01



Other non-recurring items





0.01



Income tax adjustments





(0.01)










Non-GAAP net income per share attributable to Syneron shareholders 





$                    0.06










Weighted average shares outstanding:
















Basic





35,621











Diluted





35,991


 

Syneron Medical Ltd.

Unaudited Non-GAAP Financial Measures and Reconciliation

Pro Forma Basis, Excluding Syneron Beauty

(in thousands, except per share data)

















For the three-months ended


For the six-months ended



As Reported


Syneron Beauty


Pro Forma Basis, Excluding Syneron Beauty



As Reported


Syneron Beauty


Pro Forma Basis, Excluding Syneron Beauty



6/30/2013


6/30/2013


6/30/2013



6/30/2013


6/30/2013


6/30/2013





























GAAP operating loss

$             (4,636)


$               (2,538)


$                 (2,098)



$             (7,236)


$               (4,283)


$                 (2,953)
















Stock-based compensation

1,305


111


1,194



2,326


190


2,136


Amortization of intangible assets

2,063


153


1,910



3,697


305


3,392


Remeasurement of contingent consideration 

225


-


225



543


-


543


Other non-recurring items

2,157


-


2,157



2,652


-


2,652















Non-GAAP operating income (loss)

$              1,114


$               (2,274)


$                  3,388



$              1,982


$               (3,788)


$                  5,770










































GAAP net loss attributable to Syneron shareholders

$             (4,348)


$               (2,543)


$                 (1,805)



$             (6,791)


$               (4,345)


$                 (2,446)
















Stock-based compensation

1,305


111


1,194



2,326


190


2,136


Amortization of intangible assets

2,063


153


1,910



3,697


305


3,392


Remeasurement of contingent consideration 

225


-


225



543


-


543


Other non-recurring items

2,157


-


2,157



2,652


-


2,652


Income tax adjustments

(712)


(43)


(669)



(1,105)


(87)


(1,018)















Non-GAAP net income (loss) attributable to Syneron shareholders

$                 690


$               (2,322)


$                  3,012



$              1,322


$               (3,937)


$                  5,259





























Income (Loss) per share:



























Basic













GAAP net loss per share attributable to Syneron shareholders 





$                  (0.05)







$                   (0.07)
















Stock-based compensation





0.03







0.06


Amortization of intangible assets





0.05







0.10


Remeasurement of contingent consideration 





0.01







0.02


Other non-recurring items





0.06







0.07


Income tax adjustments





(0.02)







(0.03)















Non-GAAP net income per share attributable to Syneron shareholders 





$                   0.08







$                    0.15





























Diluted













GAAP net loss attributable to Syneron shareholders 





$                  (0.05)







$                   (0.07)
















Legal settlement costs 














Stock-based compensation





0.03







0.06


Amortization of intangible assets





0.05







0.09


Remeasurement of contingent consideration 





0.01







0.02


Other non-recurring items





0.06







0.07


Income tax adjustments





(0.02)







(0.03)















Non-GAAP net income per share attributable to Syneron shareholders 





$                   0.08







$                    0.15















Weighted average shares outstanding:




























Basic





35,786







35,704
















Diluted





36,011







36,037

 

Syneron Medical Ltd.

Unaudited Non-GAAP Financial Measures and Reconciliation

Pro Forma Basis, Excluding Syneron Beauty

(in thousands, except per share data)
















For the three-months ended


For the nine-months ended



As Reported


Syneron Beauty


Pro Forma
Basis, Excluding
Syneron Beauty


As Reported


Syneron Beauty


Pro Forma
Basis, Excluding
Syneron Beauty



9/30/2013


9/30/2013


9/30/2013


9/30/2013


9/30/2013


9/30/2013



























GAAP operating loss

$             (1,126)


$               (1,054)


$                 (72)


$             (8,362)


$               (5,337)


$             (3,025)















Stock-based compensation

979


103


876


3,305


293


3,012


Amortization of intangible assets

1,672


156


1,516


5,369


461


4,908


Remeasurement of contingent consideration 

327


-


327


870


-


870


Other non-recurring items

212


-


212


2,864


-


2,864














Non-GAAP operating income (loss)

$              2,064


$                  (795)


$              2,859


$              4,046


$               (4,583)


$              8,629







































GAAP net loss attributable to Syneron shareholders

$             (1,276)


$               (1,155)


$                (121)


$             (8,067)


$               (5,500)


$             (2,567)















Stock-based compensation

979


103


876


3,305


293


3,012


Amortization of intangible assets

1,672


156


1,516


5,369


461


4,908


Remeasurement of contingent consideration 

327


-


327


870


-


870


Other non-recurring items

212


-


212


2,864


-


2,864


Income tax adjustments

(393)


(43)


(350)


(1,498)


(130)


(1,368)














Non-GAAP net income (loss) attributable to Syneron shareholders

$              1,521


$                  (939)


$              2,460


$              2,843


$               (4,876)


$              7,719



























Income (Loss) per share:

























Basic












GAAP net loss per share attributable to Syneron shareholders 





$               (0.00)






$               (0.07)















Stock-based compensation





0.02






0.08


Amortization of intangible assets





0.04






0.14


Remeasurement of contingent consideration 





0.01






0.02


Other non-recurring items





0.01






0.08


Income tax adjustments





(0.01)






(0.04)














Non-GAAP net income per share attributable to Syneron shareholders 





$                0.07






$                0.22



























Diluted












GAAP net loss attributable to Syneron shareholders 





$               (0.00)






$               (0.07)















Legal settlement costs 













Stock-based compensation





0.02






0.08


Amortization of intangible assets





0.04






0.14


Remeasurement of contingent consideration 





0.01






0.02


Other non-recurring items





0.01






0.08


Income tax adjustments





(0.01)






(0.04)














Non-GAAP net income per share attributable to Syneron shareholders 





$                0.07






$                0.21














Weighted average shares outstanding:


























Basic





36,064






35,826















Diluted





36,196






36,058














 

Syneron Medical Ltd.

Unaudited Non-GAAP Financial Measures and Reconciliation

Pro Forma Basis, Excluding Syneron Beauty


(in thousands, except per share data)

















For the three-months ended


For the twelve-months ended



As Reported


Syneron Beauty


Pro Forma Basis, Excluding Syneron Beauty


As Reported


Syneron Beauty


Pro Forma Basis, Excluding Syneron Beauty




12/31/2013


12/31/2013


12/31/2013


12/31/2013


12/31/2013


12/31/2013






























GAAP operating income (loss)

$              2,243


$               (1,997)


$              4,240


$             (6,119)


$               (7,334)


$              1,215

















Stock-based compensation

1,183


186


997


4,488


479


4,009



Amortization of intangible assets

1,636


116


1,520


7,005


577


6,428



Gain from sale of subsidiary, net of deal related costs

(6,020)


-


(6,020)


(6,020)


-


(6,020)



Remeasurement of contingent consideration 

339


-


339


1,209


-


1,209



Other non-recurring items

2,064


-


2,064


4,928


-


4,928
















Non-GAAP operating income (loss)

$              1,445


$               (1,695)


$              3,140


$              5,491


$               (6,278)


$            11,769











































GAAP net income (loss) attributable to Syneron shareholders

$              9,714


$               (2,088)


$            11,802


$              1,647


$               (7,588)


$              9,235

















Stock-based compensation

1,183


186


997


4,488


479


4,009



Amortization of intangible assets

1,636


116


1,520


7,005


577


6,428



Gain from sale of subsidiary, net of deal related costs

(6,020)


-


(6,020)


(6,020)


-


(6,020)



Remeasurement of contingent consideration 

339


-


339


1,209


-


1,209



Other non-recurring items

2,064


-


2,064


4,928


-


4,928



Income tax adjustments

(4,933)


(34)


(4,899)


(6,431)


(164)


(6,267)
















Non-GAAP net income (loss) attributable to Syneron shareholders

$              3,983


$               (1,820)


$              5,803


$              6,826


$               (6,696)


$            13,522






























Income (Loss) per share:



























Basic













GAAP net income per share attributable to Syneron shareholders 





$                0.33






$                0.26

















Stock-based compensation





0.03






0.11



Amortization of intangible assets





0.04






0.18



Gain from sale of subsidiary, net of deal related costs





(0.17)






(0.17)



Remeasurement of contingent consideration 





0.01






0.03



Other non-recurring items





0.06






0.14



Income tax adjustments





(0.14)






(0.17)
















Non-GAAP net income per share attributable to Syneron shareholders 





$                0.16






$                0.38






























Diluted













GAAP net income attributable to Syneron shareholders 





$                0.32






$                0.25

















Legal settlement costs 














Stock-based compensation





0.03






0.11



Amortization of intangible assets





0.04






0.18



Gain from sale of subsidiary, net of deal related costs





(0.16)






(0.17)



Remeasurement of contingent consideration 





0.01






0.03



Other non-recurring items





0.06






0.14



Income tax adjustments





(0.13)






(0.17)
















Non-GAAP net income per share attributable to Syneron shareholders 





$                0.16






$                0.37
















Weighted average shares outstanding:




























Basic





36,208






35,922

















Diluted





36,652






36,254
















 

 

 

SOURCE Syneron Medical Ltd.



RELATED LINKS
http://www.syneron-candela.com

More by this Source

Best of Content We Love 2014 


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.